Celator Pharma, Cephalon to extend research pact
Under the agreement, Cephalon will use Celator’s proprietary technology in an ongoing drug development and life-cycle management program at Cephalon. Celator Pharma CEO Scott Jackson said they are
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Regorafenib is an oral multi-kinase inhibitor, which targets angiogenic (VEGFR, TIE-2), stromal (PDGFR-ß) and oncogenic (RAF, RET and KIT) receptor tyrosine kinases. The randomised, double-blind, placebo-controlled, multi-centre, cross-over